| Literature DB >> 31193358 |
M Pia Chaparro1, Amanda Hughes1,2, Meena Kumari1, Michaela Benzeval1.
Abstract
The goal of this study was to evaluate how self-rated health (SRH) and objective measures of health (biomarkers) are associated, and if this association varies by gender, age, and socioeconomic position (measured by household income). Data come from the UK Household Longitudinal Study nurse visit (2010-2012), including a representative sample of adults in Great Britain (N = 15 687 maximum sample). SRH was assessed by the question "In general, would you say your health is excellent, very good, good, fair, or poor?" and dichotomized into good or poor. Indices were created for four biomarker categories based on the aspects of health they are likely to reflect, including visible weigh-related, fitness, fatigue, and disease risk biomarkers. Logistic regression models were run with SRH as the outcome and each biomarker index as a predictor, adjusting by gender, age, and income. Further, interaction terms between each biomarker index and gender, age, and income (independently) were added to test for effect modification. All biomarker indices were associated with SRH in expected directions, with the fitness index most strongly predicting SRH. Gender, age, or income modified the associations between SRH and all biomarker indices to different extents. The association between the visible weight-related biomarker index (including body mass/fat variables) and SRH was stronger for women than men and for those in higher income groups than lower income groups. Income also modified the association between SRH and the fitness biomarker index, whereas age modified the association between SRH and the fatigue biomarker index. When using SRH to investigate health inequalities, researchers and policy makers should be clear that different social groups may systematically consider different dimensions of health when reporting their SRH.Entities:
Keywords: Age; Biomarkers; Gender; Health inequalities; Income; Self-rated health; United Kingdom
Year: 2019 PMID: 31193358 PMCID: PMC6527907 DOI: 10.1016/j.ssmph.2019.100406
Source DB: PubMed Journal: SSM Popul Health ISSN: 2352-8273
Use/purpose, measurement method, data management and operationalization of the biomarkers included in the study.a
| Included biomarkers | Use/purpose | Measurement method | Data management & exclusions | Operationalization |
|---|---|---|---|---|
| Body mass index (BMI, kg/m2) | To estimate weight status | Weight measured with Tanita BF 522 digital floor scale; height measured with a portable stadiometer | Exclusions: <18 years of age; implausible BMI (<15 or >60) | BMI, continuous Weight status: BMI<18.5 = underweight; BMI between 18.5 and 24.99 = normal weight; BMI between 25 and 29.99 overweight; BMI>30 = obese |
| Waist circumference (WC, cm) | To assess central adiposity | Tape with insertion buckle; measurement taken at the midpoint between the lower rib and the upper margin of the iliac rest. Average of two measurements | Exclusions: implausible WC (<50 or >190 cm; no implausible values found in the data) | Waist circumference, continuous |
| %Body fat (%BF) | To assess adiposity | Bioelectrical impedance using a Tanita BF 522 scale; estimation based on respondent's age, gender and height (a “standard” body type was assumed) | Exclusions: implausible %BF (<5%; no implausible values found in the data) | %Body fat, continuous |
| Heart rate (HR, bpm) | To assess resting heart rate | Portable monitor Omron HEM 907. Measured as the number of beats per minute; average of three readings | Exclusions: top 99.5 (≥102 bpm) and bottom 0.5 (≤44 bpm) percentiles | HR, continuous |
| Grip strength (GS, kg) | To measure muscular strength | Smedley dynamometer. Three measurements taken with each hand; only the maximum reading for dominant hand used | Exclusions: top 99.5 (≥66 Kg) and bottom 0.5 (≤7 Kg) percentiles | GS, continuous |
| Forced expiratory volume in 1 s, percent predicted (FEV1%) | To assess lung function | NDD Easy On-PC spirometer (England and Wales only). | Data cleaning procedures: 1) if the reading for FVC was equal to the reading of FEV, these readings were considered invalid and set to missing; 2) if the ratio of FEV to FVC was >0.95, the FVC reading was considered invalid and set to missing | FEV1% and FVC%, continuous |
| C-reactive protein (CRP; mg/L) | Chronic inflammation marker | Analyzed from serum using the N Latex CRP mono immunoassay on the Behring Nephelometer II Analyzer (Dade Behring, Milton Keynes, UK) | Exclusions: CRP>10 mg/L as these reflect a current infection instead of chronic inflammation (N = 705) | CRP, continuous |
| Fibrinogen (g/L) | Chronic inflammation marker | Analyzed from citrate plasma samples using a modification of the Clauss thrombin clotting method on the IL-ACS-TOPS analyzer | Exclusions: top 99.5 (≥4.8 g/L) and bottom 0.5 (≤1.4 g/L) percentiles | Fibrinogen, continuous |
| Hemoglobin (Hb, g/L) | Indicator of iron status | Measured from whole blood samples with a spectrophotometric assay on Sysmex XE-2100 analyzer | Exclusions: top 99.5 (≥17.1 g/L) and bottom 0.5 (≤9.6 g/L) percentiles | Hb, continuous |
| Ferritin (μg/L) | Indicator of iron stores | Measured from serum samples with an electrochemiluminescent immunoassay on the Roche E170 analyzer | Exclusions: top 99.5 (≥822 μg/L) and bottom 0.5 (≤8 μg/L) percentiles | Ferritin, continuous |
| Cytomegalovirus antibody measurement (CMV) | To assess immunoscience (susceptibility to infection) | Two CMV antibodies measured: immunoglobulin G (IgG) indicating a past CMV infection, and immunoglobulin M (IgM) indicating a recent/current infection. Both measured from serum samples with an electrochemiluminescent immunoassay on the Roche E170 analyzer. For people with a positive/indeterminate IgM test, a confirmatory assay was conducted with an avidity test on the Mini VIDAS immunoassay analyzer | Categorized as ever having CMV infection vs. not | |
| Blood pressure, risk for heart disease | Portable monitor Omron HEM 907. Mean of three valid readings used | Exclusions: implausible SBP and DBP (<40 or >300 mmHg and <30 or >200 mmHg, respectively; no implausible values found in the data) | SBP and DBP, continuous | |
| To assess fat in the blood, risk for heart disease | Total cholesterol, HDL and triglycerides were measured from (non-fasting) blood serum using enzymatic methods with a Roche Modular P analyzer. Cholesterol measures were calibrated to the Center for Disease Control guidelines | Exclusions: top 99.5 and bottom 0.5 percentiles | Total cholesterol, HDL, and triglycerides continuous | |
| Glycated hemoglobin (HbA1c, mmol/mol) | Marker of undiagnosed or poorly managed type II diabetes | Measured from whole blood using HPLC cation exchange on a Tosoh G8 analyzer | Exclusions: top 99.5 (≥86 mmoL/mol) and bottom 0.5 (≤26 mmoL/mol) percentiles | HbA1c, continuous |
For more detailed information please see (Benzeval et al., 2014; McFall et al., 2014).
Also included in the disease category.
Cut-off points for sex-specific tertiles for the creation of the visible weight-related, fitness, fatigue and disease risk indices.
| Women | Men | |||
|---|---|---|---|---|
| Lowest tertile cut-off | Highest tertile cut-off | Lowest tertile cut-off | Highest tertile cut-off | |
| Body Mass Index (kg/m2) | 24.9 | 29.8 | 26.0 | 29.7 |
| Waist circumference (cm) | 82.7 | 95.4 | 94.3 | 105.0 |
| %Body fat (%BF) | 33.7 | 40.9 | 19.6 | 27.3 |
| Heart rate (bpm) | 65.0 | 73.5 | 62.0 | 71.5 |
| Grip strength (kg) | 24.0 | 30.0 | 38.0 | 47.0 |
| FEV1% | 87.5 | 100.4 | 85.7 | 98.9 |
| FVC% | 92.2 | 104.5 | 90.7 | 103.1 |
| C-reactive protein (mg/L) | 0.9 | 2.4 | 0.8 | 2.0 |
| Fibrinogen (g/L) | 2.6 | 3.0 | 2.5 | 2.9 |
| Hemoglobin (g/L) | 127.0 | 135.0 | 141.0 | 150.0 |
| Ferritin (μg/L) | 50.0 | 103.0 | 114.0 | 202.0 |
| SBP (mmHg) | 114.5 | 129.5 | 123.5 | 135.5 |
| DBP (mmHg) | 68.0 | 77.0 | 69.5 | 79.0 |
| FEV1% | 88.1 | 101.0 | 87.0 | 100.3 |
| FVC% | 92.9 | 104.9 | 92.1 | 104.4 |
| Total cholesterol (mmol/L) | 5.0 | 5.9 | 4.9 | 5.9 |
| HDL cholesterol (mmol/L) | 1.5 | 1.9 | 1.2 | 1.5 |
| Triglycerides (mmol/L) | 1.1 | 1.7 | 1.4 | 2.2 |
| HbA1c (mmol/mol) | 34.0 | 38.0 | 35.0 | 38.0 |
Weighted characteristics of the sample; mean (SE) for each biomarker and biomarker index for the sample as a whole and by gender, age, and household income; and associations between self-rated health (SRH) and biomarkers based on logistic regression models.a
| N | Freq (%) | Total | Gender | Age | Household income | Association with SRH | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Women | Men | 25-60y | ≥60y | Low | Middle | High | |||||
| 15,687 | |||||||||||
| Good | 78.84 | ||||||||||
| Bad | 21.16 | ||||||||||
| Gender | 15,687 | ||||||||||
| Women | 55.85 | 0.98 (0.90–1.07) | |||||||||
| Men | 44.15 | 1.00 | |||||||||
| 15,687 | 51.11 (0.14) | ||||||||||
| Working-age (25-60y) | 68.06 | 1.00 | |||||||||
| Retirement-age (≥60y) | 31.94 | 0.53 (0.49–0.58) | |||||||||
| 15,687 | 1741.87 (19.31) | ||||||||||
| Low | 33.95 | 0.41 (0.37–0.46) | |||||||||
| Middle | 32.39 | 0.55 (0.41–0.63) | |||||||||
| High | 33.66 | 1.00 | |||||||||
| 15,687 | |||||||||||
| Body Mass Index (kg/m2) | 28.01 (0.05) | 28.03 (0.07) | 28.00 (0.06) | 27.80 (0.06) | 28.48 (0.07) | 28.27 (0.09) | 28.19 (0.08) | 27.58 (0.07) | 0.93 (0.93–0.94) | ||
| Weight status | 0.77 | ||||||||||
| Underweight | 29.91 | 0.49 (0.30–0.82) | |||||||||
| Normal weight | 38.85 | 1.00 | |||||||||
| Overweight | 30.47 | 0.86 (0.77–0.97) | |||||||||
| Obesity | 0.44 (0.39–0.49) | ||||||||||
| Waist circumference (cm) | 94.07 (0.12) | 89.88 (0.16) | 99.37 (0.17) | 92.51 (0.16) | 97.38 (0.18) | 94.74 (0.22) | 94.47 (0.21) | 93.01 (0.20) | 0.97 (0.96–0.97) | ||
| Abdominal obesity (AO) | 30.42 | ||||||||||
| No AO | 24.40 | 1.00 | |||||||||
| At risk of AO | 45.18 | 1.00 (0.87–1.14) | |||||||||
| AO | 0.47 (0.42–0.53) | ||||||||||
| %Body fat (%BF) | 37.66 | 30.97 (0.10) | 36.66 (0.10) | 23.77 (0.12) | 30.31 (0.12) | 32.38 (0.15) | 31.75 (0.18) | 31.18 (0.16) | 29.98 (0.16) | 0.97 (0.96–0.97) | |
| Obesity based on %BF | 0.71 (0.64–0.78) | ||||||||||
| Visible index | 5.92 (0.02) | 5.95 (0.03) | 5.88 (0.03) | 5.70 (0.02) | 6.38 (0.03) | 6.06 (0.03) | 5.99 (0.03) | 5.71 (0.03) | 0.84 (0.82–0.86) | ||
| 10,636 | |||||||||||
| Heart rate (bpm) | 68.80 (0.11) | 69.91 (0.14) | 67.45 (0.17) | 69.22 (0.14) | 67.91 (0.18) | 69.63 (0.20) | 68.76 (0.19) | 68.06 (0.18) | 0.98 (0.98–0.99) | ||
| Grip strength (kg) | 34.28 (0.12) | 26.97 (0.10) | 43.15 (0.16) | 36.43 (0.16) | 29.81 (0.18) | 32.57 (0.22) | 34.33 (0.22) | 35.84 (0.21) | 1.05 (1.04–1.06) | ||
| FEV1% | 92.40 (0.17) | 93.39 (0.23) | 91.21 (0.26) | 93.49 (0.19) | 90.12 (0.35) | 90.03 (0.33) | 92.34 (0.29) | 94.68 (0.26) | 1.02 (1.02–1.03) | ||
| FVC% | 97.37 (0.16) | 98.13 (0.22) | 96.43 (0.23) | 97.62 (0.19) | 69.84 (0.31) | 95.76 (0.31) | 97.18 (0.27) | 99.05 (0.25) | 1.02 (1.02–1.03) | ||
| Fitness index | 7.93 (0.02) | 7.92 (0.03) | 7.94 (0.03) | 7.70 (0.03) | 8.41 (0.03) | 8.29 (0.04) | 7.93 (0.04) | 7.60 (0.04) | 0.80 (0.73–0.82) | ||
| 9,321 | |||||||||||
| C-reactive protein (mg/L) | 2.09 (0.02) | 2.23 (0.03) | 1.93 (0.03) | 1.94 (0.03) | 2.37 (0.04) | 2.35 (0.04) | 2.13 (0.04) | 1.81 (0.03) | 0.86 (0.84–0.88) | ||
| Fibrinogen (g/L) | 2.77 (0.01) | 2.82 (0.01) | 2.70 (0.01) | 2.67 (0.01) | 2.94 (0.01) | 2.84 (0.01) | 2.78 (0.01) | 2.68 (0.01) | 0.61 (0.55–0.69) | ||
| Hemoglobin (g/L) | 137.32 (0.15) | 130.48 (0.15) | 145.49 (0.19) | 138.01 (0.20) | 136.03 (0.22) | 137.75 (0.27) | 137.24 (0.26) | 137.94 (0.26) | 1.01 (1.00–1.01) | ||
| Anemia | 10.30 | 0.75 (0.64–0.88) | |||||||||
| Ferritin (μg/L) | 133.80 (1.29) | 92.54 (1.16) | 183.04 (2.16) | 126.08 (1.64) | 148.42 (2.07) | 127.68 (2.25) | 131.54 (2.13) | 141.79 (2.29) | 1.00 (1.00–1.00) | ||
| CMV infection | 51.7 | 0.84 (0.75–0.94) | |||||||||
| Fatigue index | 8.04 (0.02) | 8.10 (0.03) | 7.97 (0.03) | 7.86 (0.03) | 8.39 (0.03) | 8.28 (0.04) | 8.10 (0.03) | 7.76 (0.03) | 0.84 (0.81–0.87) | ||
| 6,847 | |||||||||||
| SBP (mmHg) | 126.49 (0.20) | 123.41 (0.29) | 130.19 (0.29) | 122.82 (0.25) | 133.35 (0.34) | 127.85 (0.41) | 126.38 (0.35) | 125.38 (0.34) | 0.99 (0.98–0.99) | ||
| DBP (mmHg) | 73.64 (0.13) | 72.74 (0.18) | 74.71 (0.21) | 74.31 (0.18) | 72.39 (0.21) | 73.16 (0.25) | 73.72 (0.23) | 74.00 (0.22) | 0.99 (0.98–0.99) | ||
| FEV1% | 92.76 (0.21) | 93.28 (0.29) | 92.13 (0.31) | 93.91 (0.24) | 90.60 (0.42) | 90.25 (0.41) | 92.69 (0.36) | 95.08 (0.33) | 1.02 (1.02–1.02) | ||
| FVC% | 97.92 (0.19) | 98.21 (0.27) | 97.56 (0.28) | 98.17 (0.23) | 97.44 (0.36) | 96.24 (0.38) | 97.67 (0.33) | 99.66 (0.30) | 1.02 (1.02–1.03) | ||
| Total cholesterol (mmol/L) | 5.43 (0.01) | 5.46 (0.02) | 5.39 (0.02) | 5.42 (0.02) | 5.44 (0.02) | 5.38 (0.03) | 5.39 (0.02) | 5.50 (0.02) | 1.16 (1.09–1.23) | ||
| HDL cholesterol (mmol/L) | 1.56 (0.01) | 1.68 (0.01) | 1.41 (0.01) | 1.55 (0.01) | 1.59 (0.01) | 1.54 (0.01) | 1.53 (0.01) | 1.60 (0.01) | 2.01 (1.67–2.42) | ||
| Triglycerides (mmol/L) | 1.74 (0.01) | 1.55 (0.01) | 1.96 (0.02) | 1.71 (0.02) | 1.78 (0.02) | 1.76 (0.02) | 1.75 (0.02) | 1.71 (0.02) | 0.82 (0.77–0.88) | ||
| HbA1c (mmol/mol) | 36.84 (0.08) | 36.66 (0.11) | 37.05 (0.13) | 35.40 (0.09) | 39.52 (0.13) | 37.86 (0.16) | 36.79 (0.14) | 35.97 (0.11) | 0.95 (0.94–0.96) | ||
| Disease index | 16.03 (0.04) | 16.11 (0.06) | 15.93 (0.06) | 15.62 (0.06) | 16.80 (0.06) | 16.44 (0.07) | 16.09 (0.07) | 15.60 (0.07) | 0.89 (0.87–0.91) | ||
Logistic regression models predicting reporting a “good” health and adjusted for age, gender, and household income (in tertiles).
Associations between SRH and gender, age and household income were examined with a logistic regression model with SRH as the dependent variable and gender, age, and income as independent variables (all in one model).
WC > 102 cm for men and >88 cm for women = abdominal obesity; WC between 94 and 102 cm for men and between 80 and 88 cm for women = at risk of abdominal obesity; WC < 94 for men and WC < 80 for women = normal.
%BF>30% for women and >25% for men = obesity; %BF ≤ 30% for women and %BF ≤ 25% for men = no obesity.
Biomarker indices are operationalized as continuous variables with higher values reflecting the worse outcomes in each particular category. The visible index ranges from 3 to 9; the fitness and fatigue indices from 4 to 12; and the disease index from 8 to 24.
Hemoglobin (Hb) < 130 g/L for men and Hb < 120 g/L for women = anemia; Hb ≥ 130 g/L for men and Hb ≥ 120 g/L for women = no anemia.
Fig. 1Effect modification by gender, age, and household income of the association between self-rated health and biomarker groups indices. Note: The asterisk (*) denotes a significant modifying effect, based on interaction terms added between the index and the modifying variables under study. Displayed odds ratios and 95% confidence intervals are based on stratified logistic regression analyses by gender, age, and household income groups.